Durvalumab (7) – Imfinzi®

Primarily advanced or relapsed endometrial cancer, first-line therapy, combination with carboplatin and paclitaxel; maintenance therapy

Characteristics

Start date 01.09.2024 – Marketing authorisation: 26.07.2024
Resolution 20.02.2025
INN Durvalumab
Brand name Imfinzi®
Pharm. company AstraZeneca GmbH
G-BA Procedure ID D-1091
ATC code L01FF03 PD-1/PDL-1 inhibitors (L01FF)
ICD-10 codes (AIS) C54.1Malignant neoplasm of endometrium
Alpha-ID codes (AIS) I27788Endometrial carcinoma
Therapeutic area Oncological diseases Endometrial cancer (EC)
Reason for procedure New therapeutic indication
Specialty Bundling

Therapeutic indication of the resolution

Imfinzi in combination with carboplatin and paclitaxel is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are eligible for systemic therapy, followed by maintenance treatment with Imfinzi as monotherapy in endometrial carcinoma with mismatch repair deficiency (dMMR).

Subpopulation Indication Comparator
a) Adult patients with primary advanced endometrial carcinoma (stage III or IV) or recurrent endometrial carcinoma with mismatch repair deficiency (dMMR) who have not yet received systemic therapy for the treatment of – have not yet received systemic therapy as postoperative or adjuvant therapy for the treatment of primary advanced disease – have not yet received chemotherapy for the recurrence Dostarlimab in combination with carboplatin and paclitaxel followed by Dostarlimab as monotherapy

Studies and Results

No. of studies
(best subpopulation)
1 (DUO-E) 0 (Data not accepted)
Study design
(best subpopulation)
Data not accepted (Dossier: H2H vs. ACT)
Reason for dividing into subpopulations (G-BA) Previous treatment

Adult female patients with primary advanced endometrial cancer (stage III or IV) or recurrent endometrial cancer with mismatch repair deficiency (dMMR), who, for the treatment of − the primary advanced disease, have not yet received any systemic therapy as post-operative or adjuvant therapy, − the recurrence, have not yet received any chemotherapy

  • The additional benefit is not proven.
  • The results presented from the DUO-E trial are not suitable for assessing additional benefit, as the appropriate comparator therapy specified by the G-BA (dostarlimab in combination with carboplatin and paclitaxel followed by dostarlimab as monotherapy) has not been implemented in the comparative therapy used in the DUO-E study.

Courtesy translation only, please refer to the German original.

Associated procedures

Durvalumab (12) Imfinzi® AstraZeneca GmbH Oncological diseases Adenocarcinoma of the stomach or the gastro-oesophageal junction; neoadjuvant and adjuvant combination with FLOT chemotherapy followed by adjuvant monotherapy n.d. active procedure
Durvalumab (11) Imfinzi® AstraZeneca GmbH Oncological diseases Muscle-invasive bladder cancer (MIBC), neoadjuvant/adjuvant therapy following cystectomy, in combination with gemcitabine and cisplatin 4,310–5,730 100% Indication of minor additional benefit
Durvalumab (10) Imfinzi® AstraZeneca GmbH Oncological diseases Non-advanced small cell lung cancer, following platinum-based chemoradiotherapy, monotherapy 670–1,750 100% Indication of considerable additional benefit
Durvalumab (9) Imfinzi® AstraZeneca GmbH Oncological diseases Non-small cell lung cancer, EGFR/ALK-negative, neoadjuvant/adjuvant therapy, in combination with platinum-based chemotherapy 4,540–4,660 100% additional benefit not proven
Durvalumab (7) Imfinzi® AstraZeneca GmbH Oncological diseases Primarily advanced or relapsed endometrial cancer, first-line therapy, combination with carboplatin and paclitaxel; maintenance therapy 380–1,520 100% additional benefit not proven
Durvalumab (8) Imfinzi® AstraZeneca GmbH Oncological diseases Primarily advanced or recurrent endometrial cancer, combination with carboplatin and paclitaxel; maintenance therapy, combination with olaparib 990–1,810 50% Indication of considerable additional benefit
Durvalumab (6) Imfinzi® AstraZeneca GmbH Oncological diseases Hepatocellular carcinoma, first-line, monotherapy 1,900–5,470 100% additional benefit not proven
Durvalumab (3) Imfinzi® AstraZeneca GmbH Oncological diseases Biliary tumors, first-line, combination with gemcitabine and cisplatin 1,800 100% Indication of minor additional benefit
Durvalumab (4) Imfinzi® AstraZeneca GmbH Oncological diseases Non-small cell lung cancer, EGFR/ALK-negative, first-line, combination with tremelimumab and platinum-based chemotherapy 14,470–24,660 100% additional benefit not proven
Durvalumab (5) Imfinzi® AstraZeneca GmbH Oncological diseases Hepatocellular carcinoma, first-line, combination with tremelimumab 1,900–5,470 100% additional benefit not proven
Durvalumab (2) Imfinzi® AstraZeneca GmbH Oncological diseases Small cell lung cancer (SCLC), first-line, combination with etoposide and either carboplatin or cisplatin 3,210–6,130 100% Hint for minor additional benefit
Durvalumab (1) Imfinzi® AstraZeneca GmbH Oncological diseases Non-small cell lung carcinoma (NSCLC), maintenance therapy 1,600–1,800 100% Hint for considerable additional benefit


<< List of all resolutions